Quick Answer
LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported Earnings Per Share Diluted of $1.26 (loss) per share for the year ending 2025.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. showed an increase of +20.8% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: $0.95 (loss) per share | Q3 2022: $0.89 (loss) per share | Q1 2023: $0.82 (loss) per share | Q2 2023: $1.00 (loss) per share | Q3 2023: $0.49 (loss) per share | Q1 2024: $0.43 (loss) per share | Q2 2024: $0.45 (loss) per share | Q3 2024: $0.44 (loss) per share | Q1 2025: $0.29 (loss) per share | Q2 2025: $0.29 (loss) per share | Q3 2025: $0.33 (loss) per share.
- Over the full 4 years of available data (2022 to 2025), LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s Earnings Per Share Diluted has grown by 68.4%.
- Historical annual values: Fiscal year 2025: $1.26 (loss) per share | Fiscal year 2024: $1.59 (loss) per share | Fiscal year 2023: $2.66 (loss) per share | Fiscal year 2022: $3.99 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: